News Pfizer/BioNTech begin phase 1 of COVID-19/influenza combo BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
